Showing results (111-120 of 213) with videos related to
Sort By:
Pageof 22
Journal of Acquired Immune Deficiency Syndromes (1999)|June 4, 2016
Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy InitiationJyoti S Mathad, Nikhil Gupte, Ashwin Balagopal, et al.Academic Medicine : Journal of the Association of American Medical Colleges|April 29, 2024
The Johns Hopkins Physician-Scientist Training Program to Enhance Institutional Retention and Entry Into Academic Positions: An Evaluation of Program Effectiveness and OutcomesJordina Rincon-Torroella, James Feghali, Albert Antar, et al.The Journal of Clinical Investigation|April 7, 2026
HIV causes global B-cell dysregulation and restricts HBV-specific B-cell development in an incident HBV cohortKatherine Cascino, Thomas Liechti, Eric C Seaberg, et al.The Journal of Clinical Investigation|August 14, 2019
Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearanceValerie J Kinchen, Guido Massaccesi, Andrew I Flyak, et al.SSM. Qualitative Research in Health|June 29, 2026
"That's not my silo": Navigating fragmented long COVID care in the mid-Atlantic United StatesHeang-Lee Tan, Erica Rosser, Angélica Lopez Hernandez, et al.Plos Pathogens|January 6, 2022
B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infectionClinton O Ogega, Nicole E Skinner, Andrew I Flyak, et al.Journal of Virology|May 10, 2019
Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2Michelle D Colbert, Andrew I Flyak, Clinton O Ogega, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 4, 2008
High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infectionAlleluiah Rutebemberwa, Stuart C Ray, Jacquie Astemborski, et al.Immunity|January 3, 2024
Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infectionNicole Frumento, Ariadne Sinnis-Bourozikas, Harry T Paul, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2023
Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency VirusKristen M Marks, Minhee Kang, Triin Umbleja, et al.Pageof 22